JP2024515886A5 - - Google Patents
Info
- Publication number
- JP2024515886A5 JP2024515886A5 JP2023566955A JP2023566955A JP2024515886A5 JP 2024515886 A5 JP2024515886 A5 JP 2024515886A5 JP 2023566955 A JP2023566955 A JP 2023566955A JP 2023566955 A JP2023566955 A JP 2023566955A JP 2024515886 A5 JP2024515886 A5 JP 2024515886A5
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- binding
- group
- composition according
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182639P | 2021-04-30 | 2021-04-30 | |
| US63/182,639 | 2021-04-30 | ||
| PCT/US2022/026933 WO2022232514A1 (en) | 2021-04-30 | 2022-04-29 | Compositions and methods for targeting lipid nanoparticle therapeutics to stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515886A JP2024515886A (ja) | 2024-04-10 |
| JP2024515886A5 true JP2024515886A5 (https=) | 2025-05-09 |
Family
ID=83847301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566955A Pending JP2024515886A (ja) | 2021-04-30 | 2022-04-29 | 幹細胞に対して脂質ナノ粒子治療薬を標的化するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240216523A1 (https=) |
| EP (1) | EP4330391A1 (https=) |
| JP (1) | JP2024515886A (https=) |
| CN (1) | CN117396604A (https=) |
| AU (1) | AU2022267356A1 (https=) |
| CA (1) | CA3217115A1 (https=) |
| WO (1) | WO2022232514A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| CN117460518A (zh) * | 2021-04-30 | 2024-01-26 | 宾夕法尼亚大学理事会 | Cd-90靶向的脂质纳米颗粒 |
| WO2024124143A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Hsc targeted lnp for delivery of pro-apoptotic mrna and methods of use thereof |
| CN120418427A (zh) | 2022-12-23 | 2025-08-01 | 因特利亚治疗公司 | 用于基因组编辑的系统和方法 |
| IL322368A (en) * | 2023-02-03 | 2025-09-01 | Genzyme Corp | HSC-specific antibody-conjugated lipid nanoparticles and their uses |
| WO2024229251A2 (en) * | 2023-05-02 | 2024-11-07 | The Trustees Of The University Of Pennsylvania | Hematopoietic stem cell (hsc) targeted gene editing and methods of use thereof |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025160118A1 (en) * | 2024-01-22 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents |
| CN118903476B (zh) * | 2024-10-10 | 2025-05-06 | 嘉晨西海(南昌)生物制药有限公司 | 含LNP和mRNA的组合物及其在治疗戈谢病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013200A (es) * | 2005-04-22 | 2008-03-24 | Johnson & Johnson | Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2. |
| PL2578685T3 (pl) * | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| WO2016197133A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics, Inc. | Delivering crispr therapeutics with lipid nanoparticles |
| CN112055695A (zh) * | 2018-05-01 | 2020-12-08 | 弗莱德哈钦森癌症研究中心 | 用于基因表达的纳米粒子和其用途 |
-
2022
- 2022-04-29 AU AU2022267356A patent/AU2022267356A1/en active Pending
- 2022-04-29 US US18/558,015 patent/US20240216523A1/en active Pending
- 2022-04-29 EP EP22796806.2A patent/EP4330391A1/en active Pending
- 2022-04-29 WO PCT/US2022/026933 patent/WO2022232514A1/en not_active Ceased
- 2022-04-29 JP JP2023566955A patent/JP2024515886A/ja active Pending
- 2022-04-29 CN CN202280038631.5A patent/CN117396604A/zh active Pending
- 2022-04-29 CA CA3217115A patent/CA3217115A1/en active Pending
-
2024
- 2024-10-02 US US18/904,575 patent/US20250041436A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515886A5 (https=) | ||
| Claridge et al. | Development of extracellular vesicle therapeutics: challenges, considerations, and opportunities | |
| CN1139385C (zh) | 用于脂化亲水分子的方法和组合物 | |
| Bajetto et al. | Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies | |
| JP2020533021A5 (https=) | ||
| Fritz et al. | Mesenchymal stem cells: an emerging tool for cancer targeting and therapy | |
| Mizuno et al. | Growth inhibition of glioma cells transfected with the human β-interferon gene by liposomes coupled with a monoclonal antibody | |
| Li et al. | Delivery of stem cell secretome for therapeutic applications | |
| TWI611812B (zh) | 氧化矽型生物分子載體、包含其之醫藥組成物、其製備方法及用途 | |
| Lim et al. | An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy | |
| Chen et al. | Discovery of Peptide ligands for hepatic stellate cells using phage display | |
| CA2197265A1 (en) | Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use | |
| UA120026C2 (uk) | Триалкілкатіонні ліпіди і способи їх застосування | |
| US20210322331A1 (en) | Nanocapsules for the delivery of cell modulating agents | |
| JP2014516034A5 (https=) | ||
| Rosca et al. | Emerging role of stem cells-derived exosomes as valuable tools for cardiovascular therapy | |
| Azimifar et al. | Evaluation of the efficiency of modified PAMAM dendrimer with low molecular weight protamine peptide to deliver IL‐12 plasmid into stem cells as cancer therapy vehicles | |
| WO2006007560A3 (en) | Targeted protein replacement for the treatment of lysosomal storage disorders | |
| Ji et al. | In situ cell membrane fusion for engineered tumor cells by worm-like nanocell mimics | |
| Jin et al. | Role of hydrophobic modification in spermine-based poly (β-amino ester) s for siRNA delivery and their spray-dried powders for inhalation and improved storage | |
| Zhang et al. | Engineered exosomes for tissue regeneration: from biouptake, functionalization and biosafety to applications | |
| Castro et al. | Mini-review: nucleus-targeted ribonucleases as antitumor drugs | |
| Zhou et al. | Dental mesenchymal stem cells in inflamed microenvironment: potentials and challenges for regeneration | |
| Dezawa | Macrophage-and pluripotent-like reparative Muse cells are unique endogenous stem cells distinct from other somatic stem cells | |
| Börger et al. | Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy |